KROS Stock Price, Chart, Stats & News
Keros Therapeutics Inc (KROS) does not currently pay a dividend.
KROS chart
Fundamentals
Gross margin | 99.52% |
Operating margin | 28.94% |
Pretax margin | 37.65% |
Net margin | 35.65% |
Effective tax rate | 5.31% |
ROA | 25.74% |
ROE | 14.25% |
D/E | 0.06x |
Interest coverage ratio | – |
KROS valuation
P/E | – |
P/S | 1.62x |
P/B | 1.30x |
P/CF | 3.67x |
P/FCF | 3.73x |
P/OCF | 3.67x |
PEG | 0.26x |
EV multiple | 8.04x |
About
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation.
Similar securities
Based on sector and market capitalization
